Organ-on-chip for personalised biomaterial risk assessment: PANBioRA
The goal of PANBioRA is to provide a set of tools to standardize the evaluation of new biomaterials.
This project is completed now. If interested, feel free to contact us.
Biomaterial risk assessment: introduction
Lots of medical devices, like implants, coronary stents, or fracture pins, are made of biomaterials.
The biological evaluation of new biomaterials is currently time and resource-consuming.
Moreover, once implanted, biomaterial devices often lead to complications such as inflammation or infections, showing the difficulty in assessing their innocuity and the importance of developing new tools for personalized pre-implantation diagnostics.
PANBioRA aims to provide a set of tools to standardize the evaluation of new biomaterials.
The same platform should also allow personal testing of different materials to assess the risks and choose the most appropriate for each patient.
We will share our expertise in microfluidics with this consortium of 17 partners spread across 11 countries to help develop this new set of tools.
Biomaterial risk assessment: our role
The biomaterials risk assessment will be based on standardized genotoxicity and cytotoxicity tests implemented at a microfluidic scale. The MIC is in charge of implementing a user-friendly, compact microfluidic flow control system that allows the controlled perfusion of i) organ-on-a-chip that mimics the critical barriers of the body and ii) standard on-chip cultures for cell-based cytotoxicity tests.
The microfluidic system will allow cell monitoring by conveying the supernatants from the devices to appropriate sensors to offer a read-out with quantifiable values of the toxicity of a biomaterial, the latter being developed by other partners.
Additional refined, miniaturized versions of existing genotoxicity methods are also controlled using Elveflow proprietary systems and in-house know-how.
For the PANBioRA project, we work with OEM custom fluidic system (Elveflow) to do the pressure management of different solutions in a reduced space and with LabViewTM libraries for higher compatibility and integration with the rest of the system.
Related content
In the light of this project, we have published a review on liver-on-chip technology.
Funding
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 760921 (PANBIORA project).
